2024-09-01
We’re proud to share that Julie Bouquety’s photo “L’origine du lab” has been selected for the 2023–2024 Interuniversity Photography Competition! Her image offers a creative...
At the intersection of neuroscience, aging, and regenerative medicine, the Drouin-Ouellet Lab investigates the fundamental mechanisms of Parkinson’s Disease (PD). We focus on understanding how aging contributes to PD and explore innovative cell reprogramming strategies to develop models and therapies for neurodegeneration.
We are based in the Faculty of Pharmacy at the Université de Montréal and welcome students, collaborators, and partners who share our passion for translational neurobiology.
Our lab integrates advanced in vitro human models with state-of-the-art molecular and imaging technologies to investigate the role of aging in Parkinson’s Disease. We specialize in:
We investigate whether Parkinson’s Disease is a form of accelerated aging or the result of dysfunction in specific aging pathways, using patient-derived neuronal models to pinpoint root causes and therapeutic targets.
Astrocytes in the aging brain show altered biology that may impact both disease progression and their potential for neural repair. Our lab studies astrocyte aging and their reprogramming potential to restore brain function.
Microglia exhibit a strong inflammatory response in PD. We use senescent microglial models to uncover how aging alters immune responses and contributes to neurodegeneration in Parkinson’s Disease.
Stay up to date with our recent discoveries, lab milestones, and scientific contributions in the field of aging and Parkinson’s Disease.
We’re proud to share that Julie Bouquety’s photo “L’origine du lab” has been selected for the 2023–2024 Interuniversity Photography Competition! Her image offers a creative...
Congratulations to Julie Bouquety, PhD student in our lab, on being awarded a Graduate Student Scholarship from Parkinson Canada! Julie’s work explores how age-related changes...
The cause of dopaminergic cell death in the substantia nigra of patients with Parkinson’s disease is unknown”: thus begins the Lancet paper published by Shapira et al....
Through cutting-edge models and human cellular reprogramming, we aim to understand how aging contributes to neurodegeneration and how it might be reversed.
